OP
STLN

Omni Partners’s Starling Oncology STLN Stock Holding History

Omni Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$615K Sell
61,724
-101,638
-62% -$1.08M 0.03% 182
2020
Q4 		$1.76M Buy
+163,362
New +$1.68M 0.1% 135

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Omni Partners's STLN Position: Q1 2021 in Review

Omni Partners reduced its Starling Oncology (STLN) stake by 62% in Q1 2021, selling an estimated $1.08M and leaving 61,724 shares worth $615K. The position accounts for 0.03% of the portfolio, ranked #182.

Omni Partners first reported a position in STLN in Q4 2020 and has held it in 2 quarters since. The position peaked at $1.76M in Q4 2020. 50 funds tracked by Wall St. Rank hold STLN as of Q1 2021.

  • Omni Partners held 61,724 shares of Starling Oncology worth $615K as of Q1 2021.
  • Omni Partners sold 101,638 Starling Oncology shares in Q1 2021, an estimated $1.08M.
  • Starling Oncology made up 0.03% of Omni Partners's portfolio in Q1 2021, its #182 holding.
  • Omni Partners first reported a position in Starling Oncology in Q4 2020 and has held it in 2 quarters since.
  • Omni Partners's Starling Oncology position peaked at $1.76M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.